Vinpocetine

General characteristics. Structure:

Active ingredient: 5 mg of a Vinpocetine.

Excipients: potato starch, lactoses monohydrate (sugar milk), silicon dioxide colloid (aerosil), talc, magnesium stearate.

Drug which main active ingredient is to partial derivatives of extract of a periwinkle small; intended for improvement of cerebral circulation and stimulation of a metabolism of a brain.

Is a vasodilator, counteracts adhesion of erythrocytes and thrombocytes, increases plasticity of the last, thereby reducing viscosity of blood.

Supplies a brain with oxygen and glucose, oberegayushche affects nervous cells, promoting a condition of their absolute rest and increasing number of viable cells.

The Vinpocetine improves ability to storing, promoting process of recovery of plasticity of neurons.

Possesses powerful antioxidant action. Slows down process of aging of a brain.

Pharmacological properties:

Pharmacodynamics. Vazodilatiruyushchy means. Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissue. Increases resistance of neurons to a hypoxia; facilitates glucose transport to a brain, through a blood-brain barrier; transfers process of disintegration of glucose to energetically more economical, aerobic way; selectively blocks Sa2+-zavisimuyu phosphodiesterase; increases the content of adenosinemonophosphate (AMF), a cyclic guanozinmonofosfat (tsGMF), ATP, noradrenaline, serotonin and ATF/AMF ratio in brain tissues; has antioxidant effect.

Reduces aggregation of thrombocytes and the increased viscosity of blood; increases the deforming ability of erythrocytes and blocks utilization by adenosine erythrocytes; promotes increase in return by oxygen erythrocytes.

Increases a cerebral blood stream; reduces resistance of vessels of a brain without essential change of indicators of system blood circulation. Does not render effect of "burglarizing" and strengthens blood supply, first of all, in ischemic sites of a brain.

Pharmacokinetics. It is quickly soaked up. Time of achievement of the maximum concentration in a blood plasma - 1 hour. Absorption happens, mainly, in proximal departments of digestive tract. When passing through a wall of intestines is not exposed to metabolism.

The maximum concentration in fabrics is noted in 2-4 h after intake. Communication with proteins - 66%, absolute bioavailability at intake - 7%, increases at use of drug after meal. The clearance of 66,7 l/h exceeds the plasma volume of a liver (50 l/h) that demonstrates extrahepatic metabolism.

At repeated receptions the kinetics has linear character. An elimination half-life at the person of 4,83±1,29 h. It is removed by kidneys and through intestines in the ratio 3:2. Gets through a placental barrier.

Indications to use:

• neurologic and mental symptoms at various forms of insufficiency of cerebral circulation (including a recovery stage of an ischemic or gemmoragichesky stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; atherosclerosis of vessels of a brain; posttraumatic and hypertensive encephalopathy);

• chronic vascular diseases of a choroid and a retina of an eye (owing to arteriosclerosis, a vasomotor spasm, thrombosis); the degenerative changes of a macula lutea caused by atherosclerosis or a vasomotor spasm; secondary glaucoma (owing to obturation of vessels);

• age vascular or toxic (medicamentous) hearing disorder, Menyer's disease, idiopathic sonitus, dizziness of a labyrinth origin;

• vazovegetativny manifestations of a menopausal syndrome.

Route of administration and doses:

Inside on 5 mg (1 таб.) after food. Drug is used 3 times a day. The initial daily dose makes 15 mg. Maximum daily dose of 30 mg. Duration of a course of treatment up to 3 months. Repeated courses 2-3 times a year are possible.

At diseases of kidneys or a liver drug is appointed in a usual dose.

Before cancellation, the dosage of drug should be reduced gradually.

Features of use:

Existence of a syndrome of the prolonged interval of QT and administration of drugs causing lengthening of an interval of QT demands periodic control of an ECG.

Effect of drug on ability to drive the car: the data on influence of a Vinpocetine on ability to driving and performance of work demanding speed of psychomotor reactions no.

Side effects:

From cardiovascular system: change of an ECG (ST depression, lengthening of an interval of QT), tachycardia, premature ventricular contraction, lability of arterial pressure, feeling of inflows.

From the central nervous system: sleep disorders (sleeplessness, the increased drowsiness), dizziness, a headache, the general weakness, the increased sweating.

From system of digestion: dryness in a mouth, nausea, heartburn.

Skin allergic reactions.

Interaction with other medicines:

Interaction is not observed at simultaneous use with β-adrenoblockers ((((((((((хлоранолол, Pindololum), Clopamidum, glibenclamide, digoxin, atsenokumaroly and Hydrochlorthiazidum, Imipraminum.

Simultaneous use of a Vinpocetine and Methyldopums sometimes caused some strengthening of hypotensive effect therefore at such treatment regular control of arterial pressure is required.

Increases risk of development of hemorrhagic complications against the background of a geparinoterapiya.

Despite the absence of the data confirming a possibility of interaction it is recommended to show care at co-administration with drugs of the central, antiarrhythmic and anticoagulating action.

Contraindications:

• the acute phase of a hemorrhagic stroke, coronary heart disease expressed to arrhythmia.

• hypersensitivity to any of drug components.

• pregnancy (perhaps placental bleeding and spontaneous abortions probably as a result of strengthening of placental blood supply).

• the lactation period (at use of drug it is necessary to stop breastfeeding).

• children up to 18 years (in connection with insufficiency of data).

• tablets contain lactose, in this regard patients with rare hereditary diseases, such as intolerance of a galactose, deficit of lactase or glyukozo-galaktozny malabsorption should not accept drug.

Overdose:

Symptoms: strengthening of expressiveness of side effects.

Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

Period of validity of 5 years. Not to use after the period of validity specified on packaging. To store in the dry place protected from light, at a temperature not above 25 °C in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets on 5 mg. On 10 tablets in a blister strip packaging. 1,2,3,4 or 5 blister strip packagings with the application instruction in a pack from a cardboard.